Key result
3D contrast low-dose dobutamine echo shows comparable 5-year survival to standard protocol post-STEMI.
Why the study?
The utility and safety of three-dimensional contrast low-dose dobutamine echocardiography (3DCLDDE) for evaluating myocardial viability early after STEMI were not established.
Does three-dimensional contrast low-dose dobutamine echocardiography improve safety and utility compared to standard low-dose dobutamine echocardiography in patients early after STEMI?
Does three-dimensional contrast low-dose dobutamine echocardiography improve safety and utility compared to standard low-dose dobutamine echocardiography in patients early after STEMI?
Absolute Event Rate: 89% vs 87%
p-value: p=0.13
Three-dimensional contrast low-dose dobutamine echocardiography is as safe and useful as standard low-dose dobutamine echocardiography for assessing myocardial viability early after STEMI.
Supports 3D contrast dobutamine echocardiography as feasible alternative post-STEMI; leaves open incremental value pending randomized trials.
Introduction: The aim of the study was to determine the utility and safety of three-dimensional contrast low-dose dobutamine echocardiography (3DCLDDE) in the evaluation of myocardial viability early after ST-elevation myocardial infarction (STEMI).Material and methods: We prospectively evaluated a group of 100 consecutive patients.Myocardial viability was assessed using dobutamine echocardiography in 76 patients with segmental wall motion abnormalities, including 37 patients evaluated using 3DCLDDE and 39 patients evaluated using a standard low-dose dobutamine echocardiography protocol (LDDE), alternately.Results: Single ventricular ectopic beats were observed during the test in 1 (2.5%, 1, p = 1) patient in the 3DCLDDE group, while pain (1, p = 1) dyspnea (1, p = 1), single ventricular beats (2, p = 1), and complex ventricular arrhythmia (2, p = 0.49) were noted in 4 (10%) patients in the LDDE group.Five-year survival was 89% in the 3DCLDDE group and 87% in the LDDE group.Conclusions: 3DCLDDE and LDDE are equally safe and useful in patients after STEMI.
No takes yet. Share an insight, caveat, or question.
Ścisło et al. (2016) studied ST-elevation myocardial infarction (STEMI) (n=76). Three-dimensional contrast low-dose dobutamine echocardiography (3DCLDDE) vs. Standard low-dose dobutamine echocardiography (LDDE) was evaluated on 5-year survival (p=0.13). Three-dimensional contrast low-dose dobutamine echocardiography demonstrated comparable safety and 5-year survival (89% vs 87%) to standard low-dose dobutamine echocardiography in patients early after STEMI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: